Metformin use and respiratory outcomes in asthma-COPD overlap

Abstract

Background Metformin is associated with improved respiratory outcomes in asthma; however, metformin in COPD and asthma-COPD overlap (ACO) remains unexplored. Objective To determine the association between metformin use and respiratory outcomes in COPD and ACO. Study design and methods Participants with COPD (FEV1/FVC < 0.70) in the Genetic Epidemiology of COPD study (COPDGene®) were categorized as ACO (n = 510), defined as concurrent physician-diagnosed asthma before age 40 years, or COPD alone (n = 3459). We estimated the association of baseline metformin use with (1) rate of total and severe respiratory exacerbations during follow-up, (2) cross-sectional St. George’s Respiratory Questionnaire (SGRQ) score, six-minute walk distance (6MWD), and post-bronchodilator FEV1 percent predicted (FEV1pp), and (3) 5-year change in SGRQ, 6MWD, and FEV1pp. We also examined change in SGRQ, 6MWD and FEV1pp among participants who initiated metformin during follow-up (n = 108) compared to persistent metformin non-users (n = 2080). Analyses were adjusted for sociodemographic factors, medications, and comorbidities. Results Among participants with ACO, metformin use was associated with lower rate of total (adjusted incidence rate ratio [aIRR] 0.3; 95% confidence interval [95%CI] 0.11, 0.77) and severe exacerbations (aIRR 0.29; 95%CI 0.10, 0.89). Among participants with COPD alone, there was no association between metformin use with total (aIRR 0.98; 95%CI 0.62, 1.5) or severe exacerbations (aIRR 1.3; 95% CI 0.68, 2.4) (p-interaction < 0.05). Metformin use was associated with lower baseline SGRQ score (adjusted mean difference [aMD] − 2.7; 95%CI − 5.3, − 0.2) overall. Metformin initiation was associated with improved SGRQ score (aMD –10.0; 95% CI − 18.7, − 1.2) among participants with ACO but not COPD alone (p-interaction < 0.05). There was no association between metformin use and 6MWD or FEV1pp in any comparison. Conclusions Metformin use was associated with fewer respiratory exacerbations and improved quality of life among individuals with ACO but not COPD alone. Results suggest a potential role for metformin in ACO which requires further prospective study. Trial Registry: NCT00608764

Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre–Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward

“…For example, it remains unclear if statin therapy can favorably influence noncardiovascular complications of COPD (80). Preclinical data with metformin have suggested improvement in the development of emphysema with cohort studies providing variable clinical correlates (81,82). It will be important during therapeutic trials to carefully record nonrespiratory medications.…”

Metformin Ameliorates Inflammation and Airway Remodeling of Experimental Allergic Asthma in Mice by Restoring AMPKα Activity

“…Moreover, recent observational studies of patients demonstrated that metformin use, independent of glycemic control and obesity, reduced the risk of asthma exacerbation among patients with asthma and diabetes ( Wu et al, 2021b ) and improved pulmonary outcomes among individuals with asthma-chronic obstructive pulmonary disease (COPD) overlap but not COPD alone ( Wu et al, 2021c ). Therefore, we conceived that metformin could alleviate the pathologic manifestation of chronic allergic asthma alone.…”

Mapping the global research landscape and hotspot of exercise therapy and chronic obstructive pulmonary disease: A bibliometric study based on the web of science database from 2011 to 2020

“…The mechanism of the movement was illustrated by the antioxidant, anti-inflammatory, and anti-apoptosis of the latter parts. Mechanisms included exercise-induced production and absorption of glucose in patients with COPD ( Franssen et al, 2011 ), and the action of drugs such as β receptor agonists bronchodilators ( Haarmann et al, 2015 ), metformin ( Wu et al, 2021 ), trypsin-like serine protease inhibitors ( Liang and Bowen, 2016 ), and so on.…”